INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Parikh Anand Kiran reported SNSE

Director, Chief Operating Officer · Faeth Therapeutics, Inc. · Sensei Biotherapeutics, Inc. — Employee Stock Option (right to buy)

Side
A
Value
—
Shares
1.24M
Price
—
Executed
Feb 19, 2026
Disclosed
Feb 19, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Feb 19 executedFeb 19, 2026 disclosed

SNSE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SNSE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    12
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Gift
    		G—
    100.0K sh
    		Oct 30, 2026Nov 3, 2026
    traded Oct 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SA
    Schayowitz AdamDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Oct 23, 2026Oct 27, 2026
    traded Oct 23, 2026
    		+4dSEC FORM 4

    Evidence

    9
    VH
    Vousden Karen HDirector
    FTHFaeth Therapeutics, Inc.
    Grant or award
    		A—
    25.0K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$73K
    2,891 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$14K
    580 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    1,358 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$105K
    4,212 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,777
    100 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$92K
    3,400 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$78K
    3,000 sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    27
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$2,639
    100 sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M—
    8,213 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    16
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M$52K
    45.3K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M$9,527
    8,213 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PK
    Parikh Anand KiranDirector, President and CEO
    FTHFaeth Therapeutics, Inc.
    Option exercise
    		M—
    45.3K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$23K
    1,118 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$36K
    1,797 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    46
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    1,583 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    49
    SC
    Stephenson Brian CChief Financial Officer
    FTHFaeth Therapeutics, Inc.
    Open-market purchase
    		BUY$77K
    3,329 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002111813-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 19, 2026
    Published
    Feb 19, 2026
    Ingested by INSIDER
    Nov 5, 04:16 UTC
    Last re-read
    Nov 5, 04:16 UTC

    Extracted facts

    Filer
    Parikh Anand Kiran
    Role
    Director, Chief Operating Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Sensei Biotherapeutics, Inc. — Employee Stock Option (right to buy)
    Ticker
    SNSE
    Shares
    1.24M
    Price per share
    $0
    Execution date (reported)
    Feb 19, 2026
    Owned after transaction
    1.24M shares
    Days from execution to publication
    0

    What this establishes

    Parikh Anand Kiran filed this Form 4 reporting a grant or award of SNSE on Feb 19, 2026. It became public on Feb 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Operating Officer
    Parikh Anand Kirancik:0002111813
    Issuer
    Faeth Therapeutics, Inc.cik:0001829802

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for SNSE is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.